Table 1 Clinicopathological factors associated with prognosis according to Cox proportional hazard model analysis.

From: Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast

 

Univariate analysis

Variable

No. of patients

HR

95% CI

P

Age at diagnosis

    ≥45 years

294

 

1.0 (reference)

 

    <45 years

137

3.57

1.46–8.75

0.0053

Management

    BCS

260

 

1.0 (reference)

 

    Mastectomy

80

0.89

0.25–3.17

0.863

    NSM

91

1.22

0.43–3.46

0.712

ER status

    Negative

56

 

1.0 (reference)

 

    Positive

375

0.82

0.24–2.79

0.747

PgR status

    Negative

81

 

1.0 (reference)

 

    Positive

350

0.85

0.29–2.56

0.779

HER2 amplification

    No

350

 

1.0 (reference)

 

    Yes

81

3.15

1.29–7.72

0.012

Subtype

 Luminal A like

321

 

1.0 (reference)

 

 Luminal B like

52

3.70

1.37–10.02

0.0101

    pureHER2 like

33

1.91

0.42–8.63

0.3990

    Triple negative

25

1.21

0.16–9.39

0.8540

Nuclear atypia

    Low grade

142

 

1.0 (reference)

 

    Intermediate grade

239

2.15

0.71–6.52

0.178

    High grade

50

1.76

0.32–9.65

0.513

Comedo necrosis

    No

223

 

1.0 (reference)

 

    Yes

208

1.97

0.78–4.93

0.149

 Tumor size (cm)

431

0.91

0.74–1.11

0.355

  1. HR hazard ratio, CI confidence interval, BCS breast-conserving surgery, NSM nipple-sparing mastectomy, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, luminal A like ER−/PR+/HER2−, luminal B like ER+/PR+/HER2+ or ER+/PR+/HER2−/MIB1 index high, pure HER2 like ER−/PR−/HER2 +, triple negative ER−/PR−/HER2−.
Back to article page